Sheeno Thyparambil
About Sheeno Thyparambil
Sheeno Thyparambil is a Senior Director of Research and Development at mProbe Inc., where he has worked since 2019. He has held various scientific roles at organizations such as Expression Pathology Inc., NantOmics, LLC, and the Myeloma Institute for Research and Therapy.
Current Role at mProbe Inc.
Sheeno Thyparambil serves as the Senior Director of Research and Development at mProbe Inc. since 2019. In this role, he is responsible for overseeing R&D initiatives and driving innovation within the company. His leadership contributes to the development of advanced solutions in the field of diagnostics and therapeutics. mProbe Inc. is located in Rockville, Maryland.
Previous Experience at NantOmics, LLC
Prior to his current position, Sheeno Thyparambil worked at NantOmics, LLC as a Principal Scientist from 2015 to 2019. During his four years at the company, he focused on integrating genomic data with clinical information to enhance precision medicine. His work contributed to the advancement of personalized treatment strategies in oncology.
Experience at Expression Pathology Inc.
Sheeno Thyparambil was employed at Expression Pathology Inc. as a Scientist for eight months in 2009. His role involved conducting research and developing methodologies related to pathology and diagnostics. This position provided him with valuable experience in the application of scientific principles in a clinical setting.
Postdoctoral Fellowship at Myeloma Institute for Research and Therapy
Sheeno Thyparambil completed a Post Doctoral Fellowship at the Myeloma Institute for Research and Therapy from 2008 to 2009. This position was based at the University of Arkansas for Medical Sciences. His research focused on multiple myeloma, contributing to the understanding of this complex disease.
Education and Expertise in Biochemistry and Molecular Biology
Sheeno Thyparambil earned his Ph.D. in Biochemistry and Molecular Biology from the University of Arkansas for Medical Sciences, completing his studies from 2003 to 2008. His academic background provides a strong foundation for his research and development work in the biomedical field.